Basaglar, a Lantus biosimilar, enters the domestic market

Basaglar, a biosimilar product of Lantus(Insulin Glargine), a Sanofi’s basal insulin treatment, will enter the domestic diabetic treatment market.

Lilly Korea, as of the 25^th, acquired approval of Basaglar Kwikpen and Cartridge 100IU from the Ministry of Food and Drug Safety.

Basaglar is a biologically equivalent medicine to Lantus; that is, it is a Lantus biosimilar.

Although the FDA tentat...